MediciNova Inc (MNOV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.33 (-3.48%), Market cap $0.07B, 52-week low–high $1.18 ~ $1.88.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical tri
Financial statements, price targets, institutional (13F) holdings and related news for MediciNova Inc are updated in real time on BlackAll Trade.
MediciNova Inc trades at $3.33 (-3.48%). Real-time quotes and charts are available on BlackAll Trade.
MediciNova Inc has a market cap of about $0.07B.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It devel